Filip Janku - 13 Sep 2024 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLUE	Stock Option (Right to Buy)	Award	$0	+30,000		$0.000000	30,000	13 Sep 2024	Common Stock	30,000	$7.56	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	On October 3, 2022, the Reporting Person was granted an option to purchase 30,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On September 13, 2024, the performance criteria underlying such shares were met.
F2	The shares underlying this option shall vest in full on March 13, 2026, subject to the Reporting Person's continued service on such date.